{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:53:09Z","timestamp":1793040789086,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.det.2025.03.004","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:33:15Z","timestamp":1745393595000},"page":"483-494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Systemic Therapies for Metastatic Melanoma"],"prefix":"10.1016","volume":"43","author":[{"given":"David I.","family":"Latoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5022","key":"10.1016\/j.det.2025.03.004_bib1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer\u2014a biological approach","volume":"1","author":"Burnet","year":"1957","journal-title":"Br Med J"},{"issue":"12","key":"10.1016\/j.det.2025.03.004_bib2","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1002\/cncr.23086","article-title":"Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4)","volume":"110","author":"O\u2019Day","year":"2007","journal-title":"Cancer"},{"issue":"5038","key":"10.1016\/j.det.2025.03.004_bib3","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic t lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.det.2025.03.004_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1084\/jem.183.3.725","article-title":"Human tumor antigens recognized by T lymphocytes","volume":"183","author":"Boon","year":"1996","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.det.2025.03.004_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-020-00939-6","article-title":"Dendritic cell biology and its role in tumor immunotherapy","volume":"13","author":"Wang","year":"2020","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"1","key":"10.1016\/j.det.2025.03.004_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"Chae","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.det.2025.03.004_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2025.03.004_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.det.2025.03.004_bib9","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.det.2025.03.004_bib10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.det.2025.03.004_bib11","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.det.2025.03.004_bib12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.det.2025.03.004_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"16","key":"10.1016\/j.det.2025.03.004_bib14","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.det.2025.03.004_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.det.2025.03.004_bib16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.det.2025.03.004_bib17","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.det.2025.03.004_bib18","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2025.03.004_bib19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10105","key":"10.1016\/j.det.2025.03.004_bib20","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.det.2025.03.004_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.det.2025.03.004_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.det.2025.03.004_bib23","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.det.2025.03.004_bib24","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp Ther Med"},{"issue":"7","key":"10.1016\/j.det.2025.03.004_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071823","article-title":"BRAF inhibitors: molecular targeting and immunomodulatory actions","volume":"12","author":"Proietti","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.det.2025.03.004_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.01.022","article-title":"Targeting the RAF\u2013MEK\u2013ERK pathway in cancer therapy","volume":"283","author":"Montagut","year":"2009","journal-title":"Cancer Lett"},{"issue":"6892","key":"10.1016\/j.det.2025.03.004_bib27","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.det.2025.03.004_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers"},{"issue":"13","key":"10.1016\/j.det.2025.03.004_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134576","article-title":"Targeted therapy in melanoma and mechanisms of resistance","volume":"21","author":"Czarnecka","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.det.2025.03.004_bib30","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.det.2025.03.004_bib31","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma","volume":"25","author":"Pires da Silva","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.det.2025.03.004_bib32","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.det.2025.03.004_bib33","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.det.2025.03.004_bib34","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"issue":"S11","key":"10.1016\/j.det.2025.03.004_bib35","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.30435","article-title":"Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma","volume":"123","author":"Lim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.det.2025.03.004_bib36","first-page":"61","article-title":"MEK inhibitors beyond monotherapy: current and future development","volume":"23","author":"Templeton","year":"2015","journal-title":"Cancer Immunomodulation"},{"issue":"2","key":"10.1016\/j.det.2025.03.004_bib37","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.det.2025.03.004_bib38","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.det.2025.03.004_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/mmt.15.38","article-title":"Biology and treatment of BRAF mutant metastatic melanoma","volume":"3","author":"Kong","year":"2016","journal-title":"Melanoma Manag"},{"issue":"20","key":"10.1016\/j.det.2025.03.004_bib40","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9992","key":"10.1016\/j.det.2025.03.004_bib41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.det.2025.03.004_bib42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.det.2025.03.004_bib43","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.det.2025.03.004_bib44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.det.2025.03.004_bib45","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1078-0432.CCR-21-0809","article-title":"5-year outcomes with cobimetinib plus vemurafenib in BRAFV600 mutation\u2013positive advanced melanoma: extended follow-up of the coBRIM study","volume":"27","author":"Ascierto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.det.2025.03.004_bib46","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.det.2025.03.004_bib47","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.det.2025.03.004_bib48","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.det.2025.03.004_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.det.2025.03.004_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.det.2025.03.004_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.det.2025.03.004_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000491","article-title":"Tolerability of BRAF\/MEK inhibitor combinations: adverse event evaluation and management","volume":"4","author":"Heinzerling","year":"2019","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.det.2025.03.004_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15123126","article-title":"Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies","volume":"15","author":"Plachouri","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.det.2025.03.004_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9839","key":"10.1016\/j.det.2025.03.004_bib55","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"15_suppl","key":"10.1016\/j.det.2025.03.004_bib56","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2013.31.15_suppl.9013","article-title":"An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)","volume":"31","author":"Hauschild","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.det.2025.03.004_bib57","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.det.2025.03.004_bib58","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"12","key":"10.1016\/j.det.2025.03.004_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10427","key":"10.1016\/j.det.2025.03.004_bib60","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.det.2025.03.004_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2024.07.1457","article-title":"Differential time series analysis shows decelerations in melanoma mortality prior to the widespread use of highly effective therapies","author":"Latoni","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352500018X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073386352500018X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:44:21Z","timestamp":1750959861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073386352500018X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S073386352500018X"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2025.03.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapies for Metastatic Melanoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2025.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}